ClinicalTrials.gg
RecruitingNCT07265466Updated Dec 4, 2025

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

A Phase 1 interventional study of JP-1366 and clopidogrel and JP-1366 and aspirin in Drug Drug Interaction (DDI), sponsored by Onconic Therapeutics Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Study summary

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

02

Conditions studied

  • Drug Drug Interaction (DDI)
03

In context

Lead sponsor

Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subject aged ≥ 19 years to \< 65 years at the time of screening
  • Subjects who weigh ≥ 50 kg (or ≥ 45 kg in the case of females) with (BMI) of ≥ 18.0 kg/m2 and ≤ 30.0 kg/m2
  • Subjects who have voluntarily decided to participate after fully understanding the clinical trial based on the detailed explanation given, and have provided written before the screening procedure.

Exclusion criteria

Exclusion Criteria:

  • Subject who has a history of disease in the liver, kidneys, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hematopoietic and oncological system, or cardiovascular system.
  • The Subject who has a clinically significant bleeding or a history of congenital or acquired bleeding disorders such as hemophilia
  • Subject who has a history of gastrointestinal disorders (e.g., Crohn's disease, ulcerative disease, etc.) or surgery (excluding appendectomy, hernia repair, endoscopic polypectomy, or hemorrhoidectomy, fissure, or fistula surgery) that may affect the absorption of the product.
  • The subject who has a hereditary disorder (galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption etc.).
  • Screening laboratory test showing any of the following abnormal laboratory results
  • Subjects who are judged unsuitable to participate in the study in the opinion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Part 1

    JP-1366 and clopidogrel

    Drug: JP-1366 and clopidogrel

  • Experimental
    Part 2

    JP-1366 and aspirin

    Drug: JP-1366 and aspirin

  • Experimental
    Part 3

    JP-1366 and atorvastatin

    Drug: JP-1366 and atorvastatin

  • Experimental
    Part 4

    JP-1366 and apixaban

    Drug: JP-1366 and apixaban

Interventions

  • DrugJP-1366 and clopidogrel

    Drug pages: Zastaprazan · Clopidogrel

    A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design

  • DrugJP-1366 and aspirin

    Drug pages: Zastaprazan · Aspirin

    An open-label, multiple-dosing, fixed sequence, 3-period design

  • DrugJP-1366 and atorvastatin

    Drug pages: Zastaprazan · Atorvastatin

    An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin

  • DrugJP-1366 and apixaban

    Drug pages: Zastaprazan · Apixaban

    An open-label, multiple-dosing, fixed sequence, 3-period design

06

What researchers measure

Primary outcomes

  1. [Part 1] Change in P2Y12 Reaction Unit (PRU) from baseline on day 8

    Change in P2Y12 Reaction Unit (PRU)

    Time frame: baseline on day 8

  2. [Part 2] Emax of arachidonic acid-induced platelet aggregation

    Emax of arachidonic acid-induced platelet aggregation

    Time frame: up to 48 hours post-dose on Day 1

  3. [Part 2] AUEC0-24 of arachidonic acid-induced platelet aggregation

    AUEC0-24 of arachidonic acid-induced platelet aggregation

    Time frame: up to 48 hours post-dose on Day 1

  4. [Part 2] Cmax,ss of JP-1366

    Cmax,ss of JP-1366

    Time frame: up to 24 hours post-dose on Day 5

  5. [Part 2] AUCτ,ss of JP-1366

    AUCτ,ss of JP-1366

    Time frame: up to 24 hours post-dose on Day 5

  6. [Part 2] Cmax of Aspirin

    Cmax of Aspirin

    Time frame: up to 48 hours post-dose on Day 1

  7. [Part 2] AUClast of Aspirin

    AUClast of Aspirin

    Time frame: up to 48 hours post-dose on Day 1

  8. [Part 3] Cmax,ss of JP-1366

    Cmax,ss of JP-1366

    Time frame: up to 24 hours post-dose on Day 5

  9. [Part 3] AUCτ,ss of JP-1366

    AUCτ,ss of JP-1366

    Time frame: up to 24 hours post-dose on Day 5

  10. [Part 3] Cmax,ss of Atorvastatin

    Cmax,ss of Atorvastatin

    Time frame: up to 24 hours post-dose on Day 5

  11. [Part 3] AUCτ,ss of Atorvastatin

    AUCτ,ss of Atorvastatin

    Time frame: up to 24 hours post-dose on Day 5

  12. [Part 4] Emax of Anti-Factor Xa activity

    Emax of Anti-Factor Xa activity

    Time frame: up to 48 hours post-dose on Day 5

  13. [Part 4] AUEC0-12 of Anti-Factor Xa activity

    AUEC0-12 of Anti-Factor Xa activity

    Time frame: up to 48 hours post-dose on Day 5

  14. [Part 4] Cmax,ss of JP-1366

    Cmax,ss of JP-1366

    Time frame: up to 24 hours post-dose on Day 5

  15. [Part 4] AUCτ,ss of JP-1366

    AUCτ,ss of JP-1366

    Time frame: up to 24 hours post-dose on Day 5

  16. [Part 4] Cmax,ss of Apixaban

    Cmax,ss of Apixaban

    Time frame: up to 12 hours post-dose on Day 5

  17. [Part 4] AUCτ,ss of Apixaban

    AUCτ,ss of Apixaban

    Time frame: up to 12 hours post-dose on Day 5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 4, 2025
StartActual
Nov 17, 2025
Primary completionEst.
Mar 30, 2026
CompletionEst.
Mar 30, 2026
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07265466
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Nov 17, 2025
Primary completion
Mar 30, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Dec 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zastaprazan · Clopidogrel · Aspirin · Atorvastatin · Apixaban

Start the discussion